文献速递肝病消化道肿瘤与早癌

脂肪变、HBV相关肝细胞癌、肝硬化与HBsAg清除:系统综述与Meta分析

Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis.
PubMed 文献 · Hepatology · 2023-04-17

该系统综述与Meta分析通过检索PubMed、EMBASE和Cochrane Library截至2022年2月1日的数据,纳入34项观察性研究共68268例慢性乙型肝炎患者,评估肝脂肪变与肝细胞癌、肝硬化、晚期纤维化及HBsAg清除的关联。结果显示肝脂肪变与肝细胞癌风险升高(OR 1.59,95%CI 1.12-2.26)及肝硬化风险升高(OR 1.52,95%CI 1.07-2.16)相关,同时与更高的HBsAg清除机会相关(OR 2.22,95%CI 1.58-3.10)。

要点

  • 肝脂肪变与CHB患者肝细胞癌风险升高相关(OR 1.59,95%CI 1.12-2.26)。
  • 肝脂肪变与CHB患者肝硬化风险升高相关(OR 1.52,95%CI 1.07-2.16)。
  • 肝脂肪变与更高的HBsAg清除机会相关(OR 2.22,95%CI 1.58-3.10)。

核心结论

  • 在慢性乙型肝炎患者中,肝脂肪变与肝细胞癌和肝硬化风险升高相关,但与更高的功能性治愈机会相关,提示识别合并脂肪变的重要性。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、EMBASE和Cochrane Library从建库至2022年2月1日的观察性研究,共纳入34项研究、68268例慢性乙型肝炎患者。

主要发现

  • 肝脂肪变与肝细胞癌风险升高相关(OR 1.59,95%CI 1.12-2.26;I²=72.5%)。
  • 在亚洲(OR 1.56,95%CI 1.08-2.25)、中位随访≥5年的研究(OR 2.82,95%CI 1.57-5.08)、排除饮酒的研究(OR 1.71,95%CI 1.01-2.91)及活检证实脂肪变的研究(OR 2.86,95%CI 1.61-5.06)中关联保持一致。
  • 在接受核苷(酸)类似物治疗的患者中未观察到显著关联(OR 1.05,95%CI 0.62-1.77)。
  • 肝脂肪变与肝硬化发生相关(OR 1.52,95%CI 1.07-2.16;I²=0%)。
  • 肝脂肪变与HBsAg清除相关(OR 2.22,95%CI 1.58-3.10;I²=49.0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: NAFLD and chronic hepatitis B (CHB) infection are common etiologies of HCC. The impact of hepatic steatosis on HCC in CHB, as well as its relationship with the development of cirrhosis, fibrosis, and HBsAg seroclearance, remains controversial. APPROACH AND RESULTS: Data from observational studies were collected through PubMed, EMBASE, and the Cochrane Library from inception to February 1, 2022. Outcomes of interest included the association of hepatic steatosis with HCC, cirrhosis, advanced fibrosis, and HBsAg seroclearance, expressed in terms of pooled ORs. Additional subgroup and sensitivity analyses were performed to validate the robustness of findings. A total of 34 studies with 68,268 patients with CHB were included. Hepatic steatosis was associated with higher odds of HCC (OR, 1.59; 95% CI, 1.12-2.26; I2 = 72.5%), with the association remaining consistent in Asia (OR, 1.56; 95% CI, 1.08-2.25), studies with a median follow-up duration of ≥5 years (OR, 2.82; 95% CI, 1.57-5.08), exclusion of alcohol use (OR, 1.71; 95% CI, 1.01-2.91), and biopsy-proven steatosis (OR, 2.86; 95% CI, 1.61-5.06), although no significant association was noted among nucleos(t)ide analogue-treated patients (OR, 1.05; 95% CI, 0.62-1.77). Steatosis was associated with the development of cirrhosis (OR, 1.52; 95% CI, 1.07-2.16; I2 = 0%) and HBsAg seroclearance (OR, 2.22; 95% CI, 1.58-3.10; I2 = 49.0%). CONCLUSIONS: Hepatic steatosis was associated with an increased risk of HCC and cirrhosis among patients with CHB but with a higher chance of achieving a functional cure, highlighting the importance of identifying concomitant steatosis in CHB.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Mao X, Cheung KS, Peng C, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis. Hepatology. 2023. PMID: 36111362. doi:10.1002/hep.32792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。